Vivek Roy

14.3k total citations · 1 hit paper
203 papers, 6.1k citations indexed

About

Vivek Roy is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Vivek Roy has authored 203 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Hematology, 76 papers in Oncology and 66 papers in Molecular Biology. Recurrent topics in Vivek Roy's work include Multiple Myeloma Research and Treatments (93 papers), Protein Degradation and Inhibitors (38 papers) and Chronic Lymphocytic Leukemia Research (31 papers). Vivek Roy is often cited by papers focused on Multiple Myeloma Research and Treatments (93 papers), Protein Degradation and Inhibitors (38 papers) and Chronic Lymphocytic Leukemia Research (31 papers). Vivek Roy collaborates with scholars based in United States, United Kingdom and Egypt. Vivek Roy's co-authors include Robert C. Flanigan, Nikhil C. Munshi, J. R. Caton, E. David Crawford, Scott I. Bearman, Patrick C. McGrath, Brent A. Blumenstein, Sydney E. Salmon, Shaji Kumar and Angela Dispenzieri and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Vivek Roy

189 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer

2001 1.2k citations Vivek Roy et al. profile →

Peers

Countries citing papers authored by Vivek Roy

Since Specialization

Citations

This map shows the geographic impact of Vivek Roy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivek Roy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivek Roy more than expected).

Fields of papers citing papers by Vivek Roy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vivek Roy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivek Roy. The network helps show where Vivek Roy may publish in the future.

Co-authorship network of co-authors of Vivek Roy

This figure shows the co-authorship network connecting the top 25 collaborators of Vivek Roy. A scholar is included among the top collaborators of Vivek Roy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vivek Roy. Vivek Roy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities 2024 ·Blood Cancer Journal ·Sikander Ailawadhi, (unknown), Ryan D. Frank, (unknown), David O. Hodge, (unknown), (unknown), (unknown), Ricardo Parrondo, Taimur Sher, Vivek Roy, Asher Chanan‐Khan	5
2	TRENDS OF INFLAMMATORY BOWEL DISEASE BURDEN IN THE UNITED STATES (1990-2019), PROJECTIONS OF DEATHS TO 2040: INSIGHTS FROM THE 2019 GLOBAL BURDEN OF DISEASE STUDY 2024 ·Gastroenterology ·Rahul P. Patel, Vivek Roy, (unknown), (unknown), (unknown), (unknown), Hardik Dineshbhai Desai	0
3	Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities 2023 ·Blood ·(unknown), (unknown), (unknown), (unknown), Ricardo Parrondo, Vivek Roy, Taimur Sher, Sean M. O’Connell, (unknown), (unknown), Sikander Ailawadhi	2
4	A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL) 2023 ·American Journal of Hematology ·Alissa Visram, Suzanne R. Hayman, Angela Dispenzieri, Prashant Kapoor, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, David Dingli, Rahma Warsame, Taxiarchis Kourelis, Joselle Cook, Moritz Binder, Wilson I. Gonsalves, Eli Muchtar, Nelson Leung, Vivek Roy, S. Vincent Rajkumar, Shaji Kumar	1
5	Detectable Somatic Variants Using Next Generation Sequencing (NGS) Post Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Predict for High Relapse Risk in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) 2023 ·Blood ·(unknown), Liuyan Jiang, Zhuo Li, Hemant S. Murthy, James M. Foran, Vivek Roy, Ernesto Ayala, Mohamed A. Kharfan‐Dabaja, Madiha Iqbal	0
6	Post-Autologous Hematopoietic Cell Transplant Care in the “Home Sweet Home” Setting: A Treatment Paradigm Shift 2023 ·Hematology/Oncology and Stem Cell Therapy ·Mohamed A. Kharfan‐Dabaja, Vivek Roy, Hemant S. Murthy, (unknown), Razan Mohty, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Alexis Jackson, Ricardo A. Torres‐Guzman, Antonio J. Forte, Sikander Ailawadhi, Roxana Dronca, Michael J. Maniaci	2
7	Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Madiha Iqbal, (unknown), Jonas Paludo, Allison Rosenthal, Zhuo Li, (unknown), Muhamad Alhaj Moustafa, David J. Inwards, Luis F. Porrata, Ivana N. Micallef, José C. Villasboas, Patrick B. Johnston, Stephen M. Ansell, Craig B. Reeder, Hemant S. Murthy, Vivek Roy, James M. Foran, Han W. Tun, Mohamed A. Kharfan‐Dabaja, Ernesto Ayala	2
8	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis 2020 ·Blood Cancer Journal ·Tania Jain, Katie L. Kunze, Luke Mountjoy, (unknown), Heidi Kosiorek, Nandita Khera, William J. Hogan, Vivek Roy, James L. Slack, Pierre Noël, Veena Fauble, José F. Leis, Lisa Sproat, Ayalew Tefferi, Mrinal M. Patnaik, Ruben A. Mesa, Jeanne Palmer	13
9	C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel ☆ 2020 ·Hematology/Oncology and Stem Cell Therapy ·(unknown), Zaid Abdel Rahman, Hollie Saunders, (unknown), (unknown), Allison Rosenthal, Ernesto Ayala, Han W. Tun, Hemant S. Murthy, Vivek Roy, James M. Foran, Januario E. Castro, Pramod Guru, Mohamed A. Kharfan‐Dabaja	4
10	Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia 2019 ·Blood Cancer Journal ·Vivek Kumar, Sikander Ailawadhi, (unknown), Aditya Mehta, (unknown), Taimur Sher, Vivek Roy, Prakash Vishnu, Julian A. Marin‐Acevedo, Victoria R. Alegria, Aneel Paulus, (unknown), Madiha Iqbal, Rami Manochakian, Winston Tan, Asher Chanan‐Khan, (unknown)	44
11	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis 2019 ·Biology of Blood and Marrow Transplantation ·Madiha Iqbal, Tea Reljic, Ernesto Ayala, Taimur Sher, Hemant S. Murthy, Vivek Roy, James M. Foran, Han W. Tun, Ambuj Kumar, Mohamed A. Kharfan‐Dabaja	20
12	Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis 2018 ·American Journal of Hematology ·Ayalew Tefferi, (unknown), Jeanne Palmer, James L. Slack, Vivek Roy, William J. Hogan, (unknown), Rhett P. Ketterling, Mrinal M. Patnaik	28
13	Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis 2018 ·Bone Marrow Transplantation ·Tania Jain, Katie L. Kunze, M’hamed Temkit, (unknown), Mrinal M. Patnaik, James L. Slack, Nandita Khera, William J. Hogan, Vivek Roy, Pierre Noël, José F. Leis, (unknown), Veena Fauble, Ruben A. Mesa, Jeanne Palmer	28
14	Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant 2018 ·Hematology/Oncology and Stem Cell Therapy ·(unknown), Shahrukh K. Hashmi, Maria Stevens, Angelina D. Tan, (unknown), Jeff A. Sloan, William J. Hogan, Mark R. Litzow, Vivek Roy, James M. Foran, Gerardo Colón‐Otero	3
15	DA.R-EPOCH Vs. R-CHOP for High-Risk Diffuse Large B- Cell Lymphoma: The Mayo Clinic Florida Experience 2017 ·Blood ·Bhagirathbhai Dholaria, Prakash Vishnu, Vivek Roy, Han W. Tun, Taimur Sher, Candido E. Rivera, Sikander Ailawadhi, Nancy N. Diehl, David O. Hodge, (unknown)	0
16	Comparative Analysis of Gene Expression Status to Predict Response to Initial Multiple Myeloma Treatment: Utility of the Mmrf Commpass Database in Validating Historical Findings 2017 ·Blood ·Aneel Paulus, Marie V. Coignet, Alak Manna, Mayank Sharma, Taimur Sher, Vivek Roy, Asher Chanan‐Khan, Sikander Ailawadhi	1
17	Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437 2011 ·Clinical Cancer Research ·Monica M. Reinholz, (unknown), Kathleen Tenner, David W. Hillman, Amylou C. Dueck, Timothy J. Hobday, Donald W. Northfelt, Alvaro Moreno‐Aspitia, Vivek Roy, Betsy LaPlant, Jake Allred, Philip J. Stella, Wilma L. Lingle, Edith A. Perez	45
18	Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma 2009 ·Journal of Clinical Oncology ·Martha Q. Lacy, Suzanne R. Hayman, Morie A. Gertz, Angela Dispenzieri, Francis K. Buadi, Shaji Kumar, Philip R. Greipp, John A. Lust, Stephen J. Russell, David Dingli, Robert A. Kyle, Rafaël Fonseca, P. Leif Bergsagel, Vivek Roy, Joseph Mıkhael, A. Keith Stewart, Kristina Laumann, Jacob B. Allred, Sumithra J. Mandrekar, S. Vincent Rajkumar	226
19	Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2–Positive Breast Cancer 2009 ·The Oncologist ·Vivek Roy, Edith A. Perez	65
20	Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation 2000 ·Anti-Cancer Drugs ·(unknown), (unknown), Trinh Pham, Romeo A. Mandanas, Vivek Roy, George B. Selby, Thomas H. Carter	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact